Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Identifieur interne : 003789 ( PubMed/Corpus ); précédent : 003788; suivant : 003790Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Auteurs : Ursula Schmidt-Erfurth ; Gabriele E. Lang ; Frank G. Holz ; Reinier O. Schlingemann ; Paolo Lanzetta ; Pascale Massin ; Ortrud Gerstner ; Abdelkader Si Bouazza ; Haige Shen ; Aaron Osborne ; Paul MitchellSource :
- Ophthalmology [ 1549-4713 ] ; 2014.
English descriptors
- KwdEn :
- Angiogenesis Inhibitors (adverse effects), Angiogenesis Inhibitors (therapeutic use), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Diabetes Mellitus, Type 1 (complications), Diabetes Mellitus, Type 2 (complications), Diabetic Retinopathy (drug therapy), Diabetic Retinopathy (physiopathology), Female, Humans, Intravitreal Injections, Laser Coagulation, Macular Edema (drug therapy), Macular Edema (physiopathology), Male, Middle Aged, Precision Medicine, Ranibizumab, Retina (pathology), Retreatment, Sickness Impact Profile, Surveys and Questionnaires, Time Factors, Treatment Outcome, Visual Acuity (physiology).
- MESH :
- chemical , adverse effects : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized.
- complications : Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.
- drug therapy : Diabetic Retinopathy, Macular Edema.
- pathology : Retina.
- physiology : Visual Acuity.
- physiopathology : Diabetic Retinopathy, Macular Edema.
- Female, Humans, Intravitreal Injections, Laser Coagulation, Male, Middle Aged, Precision Medicine, Ranibizumab, Retreatment, Sickness Impact Profile, Surveys and Questionnaires, Time Factors, Treatment Outcome.
Abstract
To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to diabetic macular edema (DME).
DOI: 10.1016/j.ophtha.2013.11.041
PubMed: 24491642
Links to Exploration step
pubmed:24491642Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.</title><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name><affiliation><nlm:affiliation>Department of Ophthalmology, Medical University Vienna, Vienna, Austria. Electronic address: ursula.schmidt-erfurth@meduniwien.ac.at.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Gabriele E" sort="Lang, Gabriele E" uniqKey="Lang G" first="Gabriele E" last="Lang">Gabriele E. Lang</name><affiliation><nlm:affiliation>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schlingemann, Reinier O" sort="Schlingemann, Reinier O" uniqKey="Schlingemann R" first="Reinier O" last="Schlingemann">Reinier O. Schlingemann</name><affiliation><nlm:affiliation>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Massin, Pascale" sort="Massin, Pascale" uniqKey="Massin P" first="Pascale" last="Massin">Pascale Massin</name><affiliation><nlm:affiliation>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gerstner, Ortrud" sort="Gerstner, Ortrud" uniqKey="Gerstner O" first="Ortrud" last="Gerstner">Ortrud Gerstner</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Bouazza, Abdelkader Si" sort="Bouazza, Abdelkader Si" uniqKey="Bouazza A" first="Abdelkader Si" last="Bouazza">Abdelkader Si Bouazza</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Shen, Haige" sort="Shen, Haige" uniqKey="Shen H" first="Haige" last="Shen">Haige Shen</name><affiliation><nlm:affiliation>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Osborne, Aaron" sort="Osborne, Aaron" uniqKey="Osborne A" first="Aaron" last="Osborne">Aaron Osborne</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation><nlm:affiliation>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24491642</idno><idno type="pmid">24491642</idno><idno type="doi">10.1016/j.ophtha.2013.11.041</idno><idno type="wicri:Area/PubMed/Corpus">003789</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003789</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.</title><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name><affiliation><nlm:affiliation>Department of Ophthalmology, Medical University Vienna, Vienna, Austria. Electronic address: ursula.schmidt-erfurth@meduniwien.ac.at.</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Gabriele E" sort="Lang, Gabriele E" uniqKey="Lang G" first="Gabriele E" last="Lang">Gabriele E. Lang</name><affiliation><nlm:affiliation>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Bonn, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Schlingemann, Reinier O" sort="Schlingemann, Reinier O" uniqKey="Schlingemann R" first="Reinier O" last="Schlingemann">Reinier O. Schlingemann</name><affiliation><nlm:affiliation>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Massin, Pascale" sort="Massin, Pascale" uniqKey="Massin P" first="Pascale" last="Massin">Pascale Massin</name><affiliation><nlm:affiliation>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gerstner, Ortrud" sort="Gerstner, Ortrud" uniqKey="Gerstner O" first="Ortrud" last="Gerstner">Ortrud Gerstner</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Bouazza, Abdelkader Si" sort="Bouazza, Abdelkader Si" uniqKey="Bouazza A" first="Abdelkader Si" last="Bouazza">Abdelkader Si Bouazza</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Shen, Haige" sort="Shen, Haige" uniqKey="Shen H" first="Haige" last="Shen">Haige Shen</name><affiliation><nlm:affiliation>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai, China.</nlm:affiliation></affiliation></author><author><name sortKey="Osborne, Aaron" sort="Osborne, Aaron" uniqKey="Osborne A" first="Aaron" last="Osborne">Aaron Osborne</name><affiliation><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation><nlm:affiliation>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Ophthalmology</title><idno type="eISSN">1549-4713</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiogenesis Inhibitors (adverse effects)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Diabetes Mellitus, Type 1 (complications)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Diabetic Retinopathy (drug therapy)</term><term>Diabetic Retinopathy (physiopathology)</term><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Laser Coagulation</term><term>Macular Edema (drug therapy)</term><term>Macular Edema (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Precision Medicine</term><term>Ranibizumab</term><term>Retina (pathology)</term><term>Retreatment</term><term>Sickness Impact Profile</term><term>Surveys and Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term><term>Visual Acuity (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetes Mellitus, Type 1</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetic Retinopathy</term><term>Macular Edema</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Retina</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Visual Acuity</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Diabetic Retinopathy</term><term>Macular Edema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Laser Coagulation</term><term>Male</term><term>Middle Aged</term><term>Precision Medicine</term><term>Ranibizumab</term><term>Retreatment</term><term>Sickness Impact Profile</term><term>Surveys and Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to diabetic macular edema (DME).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24491642</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>05</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.</ArticleTitle><Pagination><MedlinePgn>1045-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2013.11.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(13)01167-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to diabetic macular edema (DME).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Phase IIIb, multicenter, 12-month, randomized core study and 24-month open-label extension study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Of the 303 patients who completed the randomized RESTORE 12-month core study, 240 entered the extension study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the extension study, patients were eligible to receive individualized ranibizumab treatment as of month 12 guided by best-corrected visual acuity (BCVA) and disease progression criteria at the investigators' discretion. Concomitant laser treatment was allowed according to the Early Treatment Diabetic Retinopathy Study guidelines. Based on the treatments received in the core study, the extension study groups were referred to as prior ranibizumab, prior ranibizumab + laser, and laser.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Change in BCVA and incidence of ocular and nonocular adverse events (AEs) over 3 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 208 patients (86.7%) completed the extension study. In patients treated with ranibizumab during the core study, consecutive individualized ranibizumab treatment during the extension study led to an overall maintenance of BCVA and central retinal subfield thickness (CRST) observed at month 12 over the 2-year extension study (+8.0 letters, -142.1 μm [prior ranibizumab] and +6.7 letters, -145.9 μm [prior ranibizumab + laser] from baseline at month 36) with a median of 6.0 injections (mean, 6.8 injections; prior ranibizumab) and 4.0 (mean, 6.0 injections; prior ranibizumab + laser). In the prior laser group, a progressive BCVA improvement (+6.0 letters) and CRST reduction (-142.7 μm) at month 36 were observed after allowing ranibizumab during the extension study, with a median of 4.0 injections (mean, 6.5 injections) from months 12 to 35. Patients in all 3 treatment groups received a mean of <3 injections in the final year. No cases of endophthalmitis, retinal tear, or retinal detachment were reported. The most frequently reported ocular and nonocular adverse effects over 3 years were cataract (16.3%) and nasopharyngitis (23.3%). Eight deaths were reported during the extension study, but none were suspected to be related to the study drug/procedure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ranibizumab was effective in improving and maintaining BCVA and CRST outcomes with a progressively declining number of injections over 3 years of individualized dosing. Ranibizumab was generally well tolerated with no new safety concerns over 3 years.</AbstractText><CopyrightInformation>Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt-Erfurth</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Medical University Vienna, Vienna, Austria. Electronic address: ursula.schmidt-erfurth@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Gabriele E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holz</LastName><ForeName>Frank G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlingemann</LastName><ForeName>Reinier O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzetta</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massin</LastName><ForeName>Pascale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerstner</LastName><ForeName>Ortrud</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouazza</LastName><ForeName>Abdelkader Si</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Haige</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RESTORE Extension Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00906464</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="N">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017075" MajorTopicYN="N">Laser Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018434" MajorTopicYN="N">Sickness Impact Profile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Papp</LastName><ForeName>Andras</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seres</LastName><ForeName>Andras</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berta</LastName><ForeName>Andras</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pesztenlehrer</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Creuzot- Garcher</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emmerich</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelmann</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellner</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirchhof</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohr</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spital</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiedemann</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrage</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menchini</LastName><ForeName>Ugo</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balestrazzi</LastName><ForeName>Emilio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noci</LastName><ForeName>Nicola Delle</ForeName><Initials>ND</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciriano</LastName><ForeName>J P Martinez</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleverling</LastName><ForeName>Bert Jeroen</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Calster</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devriendt</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz-Levin</LastName><ForeName>Malaika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jürgens</LastName><ForeName>Inga</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garweg</LastName><ForeName>Justus</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tappeiner</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerding</LastName><ForeName>Heinrich</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kloos</LastName><ForeName>Patrik</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eldem</LastName><ForeName>Bora</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sobaci</LastName><ForeName>Gungor</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapran</LastName><ForeName>Ziya</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ergin</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasanreisoglu</LastName><ForeName>Berati</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arumi</LastName><ForeName>Josep Garcia</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulla</LastName><ForeName>Francisco Gomez</ForeName><Initials>FG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imaz</LastName><ForeName>Ramon Torres</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cervera</LastName><ForeName>Enrique</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Civera</LastName><ForeName>Alfredo Adan</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Jose Ruiz</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillies</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lim</LastName><ForeName>Lyndell</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vote</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharp</LastName><ForeName>Dianne</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonder</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertes</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maberley</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyd</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivier</LastName><ForeName>Sébastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24491642</ArticleId><ArticleId IdType="pii">S0161-6420(13)01167-6</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2013.11.041</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003789 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003789 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24491642
|texte= Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24491642" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |